Xanthohumol from the hop plant stimulates osteoblast differentiation by RUNX2 activation

Biochemical and Biophysical Research Communications

Volumn 409, Issue 1, 2011, Pages 82-89

  Jeong, Hyung Min ^b   Han, Eun Hee ^a   Jin, Yun Hye ^b   Choi, You Hee ^b   Lee, Kwang Youl ^b   Jeong, Hye Gwang ^a  

^a Chungnam National University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Osteoblast differentiation; RUNX2; Xanthohumol

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BONE SIALOPROTEIN; COLLAGEN; COLLAGEN TYPE 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OSTEOCALCIN; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; TUBULIN; XANTHOHUMOL;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

CELL DIFFERENTIATION; CELL LINE; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FLAVONOIDS; HUMANS; HUMULUS; OSTEOBLASTS; OSTEOGENESIS; PROPIOPHENONES; TRANSCRIPTION, GENETIC;

EID: 79956221794     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.113     Document Type: Article

References (29)

1. Kanis J.A., Gluer C.C. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos. Int. 2000, 11:192-202.
2. Kumar P., Clark M. Clinical Medicine 2002, W.B.Saunders company, Edinburgh, UK. fifth ed.
3. Ferguson N. Osteoporosis in Focus 2004, Pharmaceutical Press, London, UK.
4. Bilezikian J.P., Rubin M.R., Finkelstein J.S. Parathyroid hormone as an anabolic therapy for women and men. J. Endocrinol. Invest. 2005, 28:41-49.
5. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter D.J., Hennekens C.H., Speizer F.E. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 1997, 336:1769-1775.
6. Gustafsson J.A., Warner M. Estrogen receptor beta in the breast: role in estrogen responsiveness and development of breast cancer. J. Steroid Biochem. Mol. Biol. 2000, 74:245-248.
7. Potter S.M., Baum J.A., Teng H., Stillman R.J., Shay N.F., Erdman J.W. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am. J. Clin. Nutr. 1998, 6813:75S-1379S.
8. Alekel D.L., Germain A.S., Peterson C.T., Hanson K.B., Stewart J.W., Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am. J. Clin. Nutr. 2000, 72:844-852.
9. Clifton-Bligh P.B., Baber R.J., Fulcher G.R., Nery M.L., Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001, 8:259-265.
10. Li B., Yu S. Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biol. Pharm. Bull. 2003, 26:780-786.
11. Chen X., Garner S.C., Quarles L.D., Anderson J.J. Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. J. Nutr. Biochem. 2003, 14:342-349.
12. Hsu Y.L., Liang H.L., Hung C.H., Kuo P.L. Syringetin, a flavonoid derivative in grape and wine, induces human osteoblast differentiation through bone morphogenetic protein-2/extracellular signal-regulated kinase 1/2 pathway. Mol. Nutr. Food Res. 2009, 53:1452-1461.
13. Milligan S.R., Kalita J.C., Heyerick A., Rong H., De Cooman L., De Keukeleire D. Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J. Clin. Endocrinol. Metab. 1999, 84:2249-2252.
14. Milligan S.R., Kalita J.C., Pocock V., Van De Kauter V., Stevens J.F., Deinzer M.L., Rong H., De Keukeleire D. The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J. Clin. Endocrinol. Metab. 2000, 85:4912-4915.
15. Gerhäuser C. Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites. Mol. Nutr. Food Res. 2005, 49:827-831.
16. Miranda C.L., Stevens J.F., Helmrich A., Henderson M.C., Rodriguez R.J., Yang Y.H., Deinzer M.L., Barnes D.W., Buhler D.R. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem. Toxicol. 1999, 37:271-285.
17. Albini A., Dell'Eva R., Vené R., Ferrari N., Buhler D.R., Noonan D.M., Fassina G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J. 2006, 20:527-529.
18. Colgate E.C., Miranda C.L., Stevens J.F., Bray T.M., Ho E. Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett. 2007, 246:201-209.
19. Tobe H., Muraki Y., Kitamura K., Komiyama O., Sato Y., Sugioka T., Maruyama H.B., Matsuda E., Nagai M. Bone resorption inhibitors from hop extract. Biosci. Biotechnol. Biochem. 1997, 61:158-159.
20. Effenberger K.E., Johnsen S.A., Monroe D.G., Spelsberg T.C., Westendorf J.J. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. J. Steroid Biochem. Mol. Biol. 2005, 96:387-399.
21. Stein G.S., Lian J.B., van Wijnen A.J., Stein J.L., Montecino M., Javed A., Zaidi S.K., Young D.W., Choi J.Y., Pockwinse S.M. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004, 23:4315-4329.
22. Selvamurugan N., Pulumati M.R., Tyson D.R., Partridge N.C. Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha1. J. Biol. Chem. 2000, 275:5037-5042.
23. Qiao M., Shapiro P., Kumar R., Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J. Biol. Chem. 2004, 279:42709-42718.
24. Kim B.G., Kim H.J., Park H.J., Kim Y.J., Yoon W.J., Lee S.J., Ryoo H.M., Cho J.Y. Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics 2006, 6:1166-1174.
25. Mundlos S., Otto F., Mundlos C., Mulliken J.B., Aylsworth A.S., Albright S., Lindhout D., Cole W.G., Henn W., Knoll J.H., Owen M.J., Mertelsmann R., Zabel B.U., Olsen B.R. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997, 89:773-779.
26. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., Shimizu Y., Bronson R.T., Gao Y.H., Inada M., Sato M., Okamoto R., Kitamura Y., Yoshiki S., Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
27. Otto F., Thornell A.P., Crompton T., Denzel A., Gilmour K.C., Rosewell I.R., Stamp G.W., Beddington R.S., Mundlos S., Olsen B.R., Selby P.B., Owen M.J. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
28. Xiao G., Jiang D., Gopalakrishnan R., Franceschi R.T. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. J. Biol. Chem. 2002, 277:36181-36187.
29. Jeong H.M., Han E.H., Jin Y.H., Hwang Y.P., Kim H.G., Park B.H., Kim J.Y., Chung Y.C., Lee K.Y., Jeong H.G. Saponins from the roots of Platycodon grandiflorum stimulate osteoblast differentiation via p38 MAPK- and ERK-dependent RUNX2 activation. Food Chem. Toxicol. 2010, 48:3362-3368.